`
`
`as) United States
`
`
`
`
`
`
`
`
`a2) Patent Application Publication 10) Pub. No.: US 2006/0217311 Al
`
`
`
`
`
`
`
`
`Dix et al. Sep. 28, 2006 (43) Pub. Date:
`
`
`
`
`US 20060217311A1
`
`
`
`
`
`
`
`(54) VEGF ANTAGONIST FORMULATIONS
`
`
`
`
`Related U.S. Application Data
`
`
`
`
`(76)
`
`
`
`
`
`
`Inventors: Daniel Dix, LaGrangeville, NY (US);
`
`
`
`
`Kelly Frye, Pomona, NY (US); Susan
`
`
`
`Kautz, Albany, NY (US)
`
`
`
`
`
`
`
`
`
`(60) Provisional application No. 60/665,125, filed on Mar.
`
`
`25, 2005.
`
`
`
`
`Publication Classification
`
`
`
`;
`
`
`Correspondence Address:
`
`
`REGENERON PHARMACEUTICALS, INC
`
`
`
`
`
`
`777 OLD SAW MILL RIVER ROAD
`
`
`
`TARRYTOWN, NY 10591 (US)
`
`
`
`
`
`(21) Appl. No.:
`
`
`
`
`11/387,256
`
`
`(22)
`
`
`Filed:
`
`
`
`
`Mar. 22, 2006
`
`
`
`(51)
`
`
`
`
`
`Int. CL
`
`
`
`(2006.01)
`AGIK 38/17
`
`
`
`(2006.01)
`AGIK 31/7012
`
`
`
`(2006.01)
`AGIK 31/4172
`
`
`
`
`
`creccccccccsercecrssseeee 514/12: 514/53; 514/400
`(52) US. CD.
`
`
`ABSTRACT
`(57)
`
`
`
`
`
`
`Formulations of a vascular endothelial growth factor
`
`
`
`
`
`
`
`(VEGF)-specific fusion protein antagonist are provided
`
`
`
`
`
`including a pre-lyophilized formulation, a reconstituted lyo-
`
`
`
`
`
`
`
`philized formulation, and a stable liquid formulation. Pref-
`
`
`
`
`
`
`
`
`
`erably, the fusion protein has the sequence of SEQ ID NO:4.
`
`CELLTRION - EXHIBIT 1033
`
`CELLTRION - EXHIBIT 1033
`
`
`
`
`
`US 2006/0217311 Al
`
`
`
`Sep. 28, 2006
`
`
`
`VEGF ANTAGONIST FORMULATIONS
`
`
`
`
`CROSS-REFERENCE TO RELATED
`
`
`
`APPLICATIONS
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`[0001] This application claims the benefit under 35 USC §
`
`
`
`
`
`
`
`
`119(c) of U.S. Provisional 60/665,125 filed 25 Mar. 2005,
`
`
`
`
`
`
`which application is herein specifically incorporated by
`
`
`
`reference in its entirety.
`
`BACKGROUND OF INVENTION
`
`
`
`[0002]
`
`
`
`
`
`
`
`1. Field of the Invention
`
`
`
`
`
`
`[0003] The present inventionis directed to pharmaceutical
`
`
`
`
`
`
`formulations comprising agents capable of inhibiting vas-
`
`
`
`
`
`
`
`
`
`cular endothelial growth factor (WEGF), and to methods for
`
`
`
`
`
`
`
`
`making andusing such formulations. The invention includes
`
`
`
`
`
`pharmaceutical formulations having increased stability.
`2. Statement of Related Art
`
`
`
`
`
`
`[0004]
`
`
`
`
`
`
`
`
`[0005] Vascular endothelial growth factor (VEGF) expres-
`
`
`
`
`
`
`
`sion is nearly ubiquitous in human cancer, consistent with ils
`
`
`
`
`
`
`role as a key mediator of tumor neoangiogenesis. Blockade
`
`
`
`
`
`
`
`
`
`
`of VEGF function, by binding to the molecule or its
`
`
`
`
`
`
`
`VEGFR-2 receptor, inhibits growth of implanted tumorcells
`
`
`
`
`
`
`
`
`in multiple different xenograft models (see, for example,
`
`
`
`
`
`
`
`Gerberet al. (2000) Cancer Res. 60:6253-6258). A soluble
`
`
`
`
`
`
`VEGF-specific fusion protein antagonist, termed a “VEGF
`
`
`
`
`
`
`
`
`
`
`trap” has been described (Kimet al. (2002) Proc. Natl. Acad.
`
`
`
`
`
`
`
`
`Sci. USA 99:11399-404; Holash et al. (2002) Proc. Natl.
`
`
`
`
`
`
`
`
`Acad. Sci. USA 99:11393-8), which applications are spe-
`
`
`
`
`
`cifically incorporated by reference in their entirety.
`
`
`
`
`
`
`
`[0006] Lyophilization (freeze drying under controlled con-
`
`
`
`
`
`
`
`
`ditions) is commonlyused for long term storage of proteins.
`
`
`
`
`
`
`
`The lyophilized protein is substantially resistant to degra-
`
`
`
`
`
`
`
`dation, aggregation, oxidation, and other degenerative pro-
`
`
`
`
`
`
`
`
`
`cesses while in the freeze-dried state (see, for example, U.S.
`
`
`
`Pat. No. 6,436,897).
`
`BRILT SUMMARY OP TIE INVENTION
`
`
`
`
`
`
`
`
`
`
`
`
`[0007]
`Stable formulations of a VEGF-specific fusion
`
`
`
`
`
`
`
`protein antagonist are herein provided. The pharmaceuti-
`
`
`
`
`
`
`
`cally acceptable formulations of the invention comprise the
`
`
`
`
`
`
`VEGF“trap” antagonist with a pharmaceutically acceptable
`
`
`
`
`
`
`
`carrier. In specific embodiments, liquid and freeze-dried, or
`
`
`
`
`lyophilized formulations are provided.
`
`
`
`
`
`
`
`
`
`the invention features a stable
`In a first aspect,
`[0008]
`
`
`
`
`
`
`
`liquid formulation of a VEGF-specific fusion protein
`
`
`
`
`
`
`antagonist, comprising a fusion protein comprising, a recep-
`
`
`
`
`
`tor componentconsisting essentially of an immunoglobulin-
`
`
`
`
`
`
`
`
`like (Ig) domain 2 of a first VEGF receptor and Ig domain
`
`
`
`
`
`
`
`
`3 of a second VEGF receptor, and a multimerizing compo-
`nent, one or more buffers, and one or more thermalstabi-
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`lizers. In a specific embodiment of the VEGF-specific fusion
`
`
`
`
`
`
`
`
`
`protein antagonist, the first VEGF receptor is Flt] and the
`
`
`
`
`
`
`
`
`
`
`second VEGFreceptor is Flk1 or Flt4. In a more specific
`
`
`
`
`
`
`
`
`embodimentthe fusion protein has the amino acid sequence
`
`
`
`
`
`
`
`
`
`of SEQ ID NO:2 or SEQ ID NO:4. In one embodiment, the
`
`
`
`
`
`
`
`buffer is a phosphate buffer and/or citrate. More preferably,
`
`
`
`
`
`
`
`
`
`the buffers are phosphate andcitrate. In one embodiment, the
`
`
`
`
`
`
`
`
`thermal stabilizers are NaCl and/or sucrose. More prefer-
`
`
`
`
`
`
`
`
`
`ably, the thermal stabilizers are both NaCl and sucrose.
`
`
`
`
`
`
`
`
`
`
`
`Ina specific embodiment, the stable liquid formu-
`[0009]
`
`
`
`
`
`
`
`lation of a VEGF-specific fusion protein antagonist com-
`
`
`
`
`
`
`
`prises 1-10 mM phosphate buffer, 1-10 mM citrate, 25-150
`
`
`
`
`
`
`
`
`
`mM NaCl, 5-30% sucrose, 10-50 mg/ml of the fusion
`
`
`
`
`
`
`
`protein, at a pH of about 6-6.5. In a more specific embodi-
`
`
`
`
`
`
`
`ment, the stable liquid formulation comprises 5 mM phos-
`
`
`
`
`
`
`
`
`
`phate buffer, 5 mM citrate buffer, 100 mM NaCl, 20%
`
`
`
`
`
`
`
`sucrose, 25 mg/mlof the fusion protein, at a pH of about 6.0.
`
`
`
`
`
`
`
`Additionally, polysorbate may be present, for example 0.05-
`
`
`
`
`
`
`
`
`0.15%polysorbate 20. The stable liquid formulation of the
`
`
`
`
`
`
`
`VEGF-specific fusion protein antagonist of the invention
`
`
`
`
`
`
`exhibits little or no precipitation after storage of a 25 mg/ml
`VEGFformulation for about 6 months at -80° C.and little
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`or no precipitation after storage for 6 months at 5° C.
`
`
`
`
`
`
`
`
`
`
`
`[0010]
`Ina second aspect, the invention features a high
`
`
`
`
`
`
`concentration stable liquid formulation of a VEGFantago-
`
`
`
`
`
`
`
`
`nist comprising 1-50 mM histidine, 25-150 mM NaCl,
`
`
`
`
`
`
`5-30% sucrose, 50-100 mg/mlof the fusion protein, at a pH
`
`
`
`
`
`
`
`
`
`of about 6-6.5, and either 0.1-0.5%polysorbate or 1-5%
`
`
`
`
`
`
`
`PEG.In a morespecific embodiment,the high concentration
`
`
`
`
`
`
`
`
`stable liquid formulation comprises 10 mM histidine, 50
`
`
`
`
`
`
`
`
`mM NaCl, 5-20% sucrose, 50-100 mg/ml of the fusion
`
`
`
`
`
`
`
`protein, at a pH of about 6.0-6.5, with either 0.1% polysor-
`
`
`
`
`
`
`
`
`
`bate (c.g., polysorbate 20) or 3% PEG (c.g., PEG 3350). The
`
`
`
`
`
`
`
`high concentration stable liquid formulation of the VEGF-
`
`
`
`
`
`
`
`specific fusion protein antagonist of the invention cxhibits
`
`
`
`
`
`
`
`less than about 3% degradation after 15 months ofstorage at
`
`
`
`
`
`
`
`
`
`
`
`
`
`5° C. (75 or 100 mg/ml VEGFtrap protein) or less than
`
`
`
`
`
`
`
`about 1.5% degradation after 24 months (50 mg/ml).
`
`
`
`
`
`
`
`
`
`[0011]
`the invention features a pre-
`In a third aspect,
`
`
`
`
`
`
`lyophilized formulation of a vascular endothelial growth
`
`
`
`
`
`
`factor (VEGF)-specific fusion protein antagonist, compris-
`
`
`
`
`
`
`
`ing a (i) fusion protein comprising a receptor component
`
`
`
`
`
`
`consisting essentially of an immunoglobulin-like ([g)
`
`
`
`
`
`
`
`
`domain 2 of a first VEGF receptor and Ig domain 3 of a
`
`
`
`
`
`
`
`second VEGF receptor, and a multimerizing component,(i1)
`
`
`
`
`
`
`
`
`
`
`a buffer, (111) an organic co-solvent or bulking agent, and(iv)
`
`
`
`
`
`
`
`one or more lyoprotectants. In various embodiments, the
`
`
`
`
`
`
`
`buffer is histidine, the organic co-solvent or bulking agentis
`
`
`
`
`
`
`
`
`
`PEG,and the lyoprotectant(s) is at least one of glycine and
`
`
`
`
`
`
`
`sucrose. In one embodiment, the pre-lyophilized. formula-
`
`
`
`
`
`
`
`tion of the invention does not contain a preservative.
`
`
`
`
`
`
`
`In one embodiment of the pre-lyophilized formu-
`[0012]
`
`
`
`
`
`
`
`lation of the invention, the formulation comprises 5-50 mM
`
`
`
`
`
`
`histidine, 0.1-3.0% PEG, 0.25-3.0% glycine, 0.5-6.0%
`
`
`
`
`
`
`
`sucrose, and 5-75 my/ml of the fusion protein, al a pH of
`
`
`
`
`
`
`
`about 6.0-6.5. In any embodiment, the pre-lyophilized for-
`
`
`
`
`
`
`
`mulation may further comprise up to 0.05 mM citrate and/or
`
`
`
`
`
`
`0.003-0.005% polysorbate. The polysorbate present maybe,
`
`
`
`
`for example, polysorbate 20.
`
`
`
`
`
`
`
`[0013]
`Ina more specific embodiment, the pre-lyophilized
`
`
`
`
`
`
`
`formulation comprises about 10 mM histidine, about 1.5%
`
`
`
`
`
`
`
`
`
`PEG 3350, about 0.75% glycine, about 2.5% sucrose, and
`
`
`
`
`
`
`
`about 12.5 to 75 mg/ml VEGF-specific fusion protein, at a
`
`
`
`
`
`
`
`
`pH of about 6.25.
`In specific embodiments,
`the fusion
`
`
`
`
`
`
`
`protein comprises the protein sequence of SEQ ID NO:4,
`
`
`
`
`
`
`
`present as a multimer, e.g., a dimer. In separate embodi-
`
`
`
`
`
`
`
`ments, the reconstituted formulation is 2 times the concen-
`
`
`
`
`
`
`
`tration of the pre-lyophilized formulation, e.g., a 20 mg
`
`
`
`
`
`fusion protein/ml! pre-lyophilized formulation is reconsti-
`
`
`
`
`
`
`
`tuted to a final formulation of 60 mg fusion protein/ml.
`
`
`
`
`
`
`Generally, the lyophilized formulation is reconstituted with
`
`
`
`
`
`US 2006/0217311 Al
`
`
`
`Sep. 28, 2006
`
`
`
`
`
`
`
`
`
`
`
`
`sterile water suitable for injection. In one embodiment, the
`
`
`
`
`
`reconstitution liquid may be bacteriostatic water.
`
`
`
`
`
`
`[0014]
`In a preferred embodiment,
`the pre-lyophilized
`
`
`
`
`
`
`
`formulation consists essentially of about 10 mM histidine,
`
`
`
`
`
`
`
`
`
`about 1.5% PEG 3350, about 0.75% glycine, about 2.5%
`
`
`
`
`
`
`
`
`sucrose, and about 50 mg/mlofthe fusion protein having the
`
`
`
`
`
`
`sequence of SEQ ID NO:4 as a dimer, at a pH of about 6.25.
`
`
`
`
`
`
`
`
`
`Citrate (less than or equal to about 0.02 mM) and/or polysor-
`
`
`
`
`
`
`
`
`bate (less than or equal to about 0.0005%) may be present.
`
`
`
`
`
`
`
`Optionally, the pre-lyophilized formulation does not contain
`
`
`
`
`
`
`
`
`a preservative, a phosphate buffer, and/or more than trace
`
`
`
`
`
`
`amounts of NaCl. In one embodiment, the pre-lyophilized
`
`
`
`
`
`
`formulation consists of about 10 mM histidine, about 1.5%
`
`
`
`
`
`
`
`
`
`PEG 3350, about 0.75% glycine, about 2.5% sucrose, and
`
`
`
`
`
`
`
`about 50 mg/ml of the VEGFtrap protein (SEQ ID NO:4),
`
`
`
`
`
`
`pH 6.3, and upon reconstitution contains 20 mM histidine,
`
`
`
`
`
`
`
`
`
`3% PEG, 1.5% glycine, about 5% sucrose, and about 100
`
`
`
`mg/ml VEGFtrap protein.
`
`
`
`
`
`
`
`
`[0015]
`Ina fourth aspect, the invention features a method
`
`
`
`
`
`of producing a lyophilized formulation of a VEGF-specific
`
`
`
`
`
`
`
`fusion protein antagonist, comprising subjecting the pre-
`
`
`
`
`lyophilized formulation of the invention to lyophilization to
`
`
`
`
`
`
`generate a lyophilized formulation. The lyophilized formu-
`
`
`
`
`
`
`
`
`lation may be lyophilized by any method knownin the art
`
`
`
`for lyophilizing a liquid.
`
`
`
`
`
`
`
`
`[0016]
`In a fitth related aspect, the invention features a
`
`
`
`
`
`method ofproducing a reconstituted lyophilized formulation
`
`
`
`
`
`
`of a VIGI'-specific fusion protein antagonist, comprising
`
`
`
`
`
`
`reconstituting the lyophilized formulation ofthe invention to
`a reconstituted formulation. In one embodiment, the recon-
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`stituted formulation is twice the concentration of the pre-
`
`
`
`
`
`
`
`lyophilized formulation, e.g., the method of the invention
`
`
`
`
`
`comprises: (a) producing a pre-lyophilized formulation of a
`
`
`
`
`
`
`
`VEGF-specific fusion protein antagonist, (b) subjecting the
`
`
`
`
`
`
`pre-lyophilized formulation of step (a) to lyophilization; and
`
`
`
`
`
`
`
`(c) reconstituting the lyophilized formulation of step (b).
`
`
`
`
`
`
`
`In specific embodiments of the method ofproduc-
`[0017]
`
`
`
`
`
`ing a reconstituted lyophilized formulation, a pre-lyo-
`
`
`
`
`
`
`
`
`philized solution is present in a vial as a 25 mg VEGE-
`
`
`
`
`
`
`
`
`specific fusion protcim antagonist per ml solution of pre-
`
`
`
`
`
`
`lyophilized
`formulation, which
`is
`lyophilized
`and
`
`
`
`
`
`
`
`reconstituted to an 50 mg/ml solution. In another embodi-
`
`
`
`
`
`
`ment, a 30 mg/m] pre-lyophilized solution is lyophilized and
`
`
`
`
`
`
`
`reconstituted to a 60 mg/ml solution. In another embodi-
`
`
`
`
`
`
`ment, a 40 mg/mlpre-lyophilized solution is lyophilized and
`
`
`
`
`
`
`
`reconstituted to a 80 mg/ml solution. In another embodi-
`
`
`
`
`
`
`ment, a 12.5 mg/ml pre-lyophilized solution is lyophilized
`
`
`
`
`
`
`and reconstituted to a 25 mg/ml solution. In another embodi-
`
`
`
`
`
`
`ment, a 50 mg/ml pre-lyophilized solution is lyophilized and
`
`
`
`
`
`
`
`reconstituted to a 100 mg/ml solution. In another embodi-
`
`
`
`
`
`
`ment, a 75 mg/ml pre-lyophilized solutionis lyophilized and
`
`
`
`
`
`
`
`reconstituted to a 150 mg/ml solution. Preferably, the recon-
`
`
`
`
`
`
`
`stituted lyophilized formulation does not contain a preser-
`valive.
`
`
`
`
`
`
`
`
`
`[0018] Other objects and advantages will become apparent
`
`
`
`
`
`
`from a review of the ensuing detailed description.
`
`
`
`DETAILED DESCRIPTION OF THE
`
`
`
`
`INVENTION
`
`
`
`
`
`
`
`
`
`
`
`[0019] The present invention is not limited to particular
`
`
`
`
`
`
`
`methods, and experimental conditions described, as such
`
`
`
`
`
`
`
`
`methods and conditions mayvary.It is also to be understood
`
`
`
`
`
`
`
`
`
`the terminology used herein is for the purpose of
`that
`
`
`
`
`
`
`
`describing particular embodimentsonly, and is not intended
`
`
`
`
`
`
`
`
`
`to be limiting unless indicated, since the scope of the present
`
`
`
`
`
`
`
`invention will be limited only by the appended claims.
`
`
`
`
`
`
`
`
`[0020] As used in this specification and the appended
`
`
`
`
`
`
`
`
`
`
`claims, the singular forms “a”, “an”, and “the”include plural
`
`
`
`
`
`
`
`references unless the context clearly dictates otherwise.
`
`
`
`
`
`
`
`
`Thus for example, references to “a method” include one or
`
`
`
`
`
`
`
`
`
`more methods, and/or steps of the type described herein
`
`
`
`
`
`
`
`
`and/or which will become apparent to those persons skilled
`
`
`
`
`
`
`
`in the art upon reading this disclosure.
`
`
`
`
`
`
`
`
`[0021] Unless stated otherwise, all technical and scientific
`
`
`
`
`
`
`
`
`
`terms and phrases used herein have the same meaning as
`
`
`
`
`
`
`
`
`commonly understood by one of ordinary skill in the art to
`
`
`
`
`
`
`
`
`which the invention belongs. Although any methods and
`
`
`
`
`
`
`
`materials similar or equivalent to those described herein can
`
`
`
`
`
`
`
`
`
`be usedin the practice or testing of the present invention, the
`
`
`
`
`
`
`
`
`preferred methods and materials are now described. All
`
`
`
`
`
`
`
`publications mentioned herein are incorporated herein by
`reference.
`
`
`
`
`
`General Description
`
`
`
`
`
`
`[0022]
`Safe handling and administration of formulations
`
`
`
`
`
`
`comprising proteins represent significant challenges to phar-
`
`
`
`
`
`
`maceutical formulators. Proteins possess unique chemical
`
`
`
`
`
`
`
`and physical properties that present stability problems: a
`
`
`
`
`
`
`
`
`variety of degradation pathways exist for proteins, impli-
`
`
`
`
`
`
`
`cating both chemical and physical
`instability. Chemical
`
`
`
`
`
`
`instability includes deamination, aggregation, clipping of
`
`
`
`
`
`
`
`the peptide backbone, and oxidation of methionineresidues.
`
`
`
`
`
`
`Physical instability encompasses many phenomena, includ-
`
`
`
`
`ing, for example, aggregation.
`
`
`
`
`
`
`
`[0023] Chemical and physical stability can be promoted
`
`
`
`
`
`
`
`by removing water from the protein. Lyophilization (freeze-
`
`
`
`
`
`
`
`drying under controlled conditions) is commonly used for
`
`
`
`
`
`
`
`long-term storage of proteins. The lyophilized protein is
`
`
`
`
`
`
`substantially resistant to degradation, aggregation, oxida-
`
`
`
`
`
`
`
`
`tion, and other degenerative processes while in the freeze-
`
`
`
`
`
`
`
`dried state. The lyophilized protein is normally reconstituted
`
`
`
`
`
`
`with water optionally containing a bacteriostatic preserva-
`
`
`
`
`
`
`tive (c.g., benzyl alcohol) prior to administration.
`Definitions
`
`
`
`
`
`
`
`
`
`[0024]
`‘The term “carricr’” includes a dilucnt, adjuvant,
`
`
`
`
`
`
`
`excipient, or vehicle with which a composition is adminis-
`
`
`
`
`
`
`
`
`
`tered. Carriers can include sterile liquids, such as,
`for
`
`
`
`
`
`
`
`
`example, water andoils, including oils of petroleum, animal,
`
`
`
`
`
`
`
`vegetable or synthetic origin, such as, for example, peanut
`
`
`
`
`
`
`
`
`
`oil, soybean oil, mineral oil, sesame oil and thelike.
`
`
`
`
`
`
`[0025] The term “excipient” includes a non-therapeutic
`
`
`
`
`
`agent added to a pharmaceutical composition to provide a
`
`
`
`
`
`
`desired consistency or stabilizing effect. Suitable pharma-
`
`
`
`
`
`
`
`ceutical excipients include, for example, starch, glucose,
`
`
`
`
`
`
`
`
`
`lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel,
`
`
`
`
`
`
`
`sodium stearate, glycerol monostearate, talc, sodium chlo-
`
`
`
`
`
`
`
`
`ride, dried skim milk, glycerol, propylene, glycol, water,
`ethanol and thelike.
`
`
`
`
`
`
`
`
`
`
`
`[0026] The term “lyophilized”or “freeze-dried” includes a
`
`
`
`
`
`
`
`
`state of a substance that has been subjected to a drying
`
`
`
`
`
`
`procedure such as lyophilization, where at
`least 50% of
`moisture has been removed.
`
`
`
`
`
`
`
`
`
`US 2006/0217311 Al
`
`
`
`Sep. 28, 2006
`
`
`
`
`
`
`
`
`
`
`[0027] The phrase “bulking agent” includes a compound
`
`
`
`
`
`
`
`that is pharmaceutically acceptable and that adds bulk to a
`
`
`
`
`
`
`
`
`lyo cake. Generally, acceptable bulking agents known to the
`
`
`
`
`
`
`
`art include, for example, carbohydrates,
`including simple
`
`
`
`
`
`
`
`
`sugars such as dextrose,ribose, fructose andthelike, alcohol
`
`
`
`
`
`
`
`sugars such as mannitol, inositol and sorbitol, disaccharides
`
`
`
`
`
`
`
`includingtrehalose, sucrose and lactose, naturally occurring
`
`
`
`
`
`
`polymers such as starch, dextrans, chitosan, hyaluronate,
`
`
`
`
`
`
`
`
`proteins (e.g., gelatin and serum albumin), glycogen, and
`
`
`
`
`
`
`
`synthetic monomers and polymers. In the formulations of
`
`
`
`
`
`
`
`
`the invention, PEG 3350 is an organic co-solvent which is
`
`
`
`
`
`
`
`
`used to stabilize the fusion protein when agitated, mixed, or
`
`
`
`
`
`
`
`handled, and as a bulking agent to help produce an accept-
`able bulk.
`
`
`
`
`
`
`
`
`
`
`
`
`[0028] The term “lyoprotectant” includes a substance that
`
`
`
`
`
`may be addedto a freeze-dried or lyophilized formulation to
`
`
`
`
`
`
`
`
`help maintain protein structure when freeze-dried or lyo-
`
`philized.
`
`
`
`
`
`[0029] A “preservative” includes a bacteriostatic, bacte-
`
`
`
`
`
`
`
`riocidal, fungistatic or fungicides compound that is gener-
`
`
`
`
`
`
`ally added to formulations to retard or climinate growth of
`
`
`
`
`
`
`bacteria or other contaminating microorganisms in the for-
`
`
`
`
`
`
`
`mulations. Preservatives include, for example, benzy] alco-
`
`
`
`
`
`
`hol, phenol, benzalkonium chloride, m-cresol, thimerosol,
`
`
`
`
`
`
`chlorobutanol, methylparaben, propylparaben and the like.
`
`
`
`
`
`
`Other examples of pharmaceutically acceptable preserva-
`tives can be found in the USP.
`
`
`
`
`
`
`
`VEGF Antagonists
`
`
`
`
`
`
`
`
`[0030] An VEGF antagonist is a compound capable of
`
`
`
`
`
`
`
`
`blocking or inhibiting the biological action of vascular
`
`
`
`
`
`
`
`
`endothelial growth factor (VEGF), and includes fusion pro-
`
`
`
`
`
`
`
`teins capable of trapping VEGF. In a preferred embodiment,
`
`
`
`
`
`
`
`
`the VEGFantagonist is the fusion protein of SEQ ID NO:2
`
`
`
`
`
`
`
`or 4; more preferably, SEQ ID NO:4. In specific embodi-
`
`
`
`
`
`
`ments, the VEGF antagonist is expressed in a mammalian
`
`
`
`
`
`
`
`
`cell line such as a CHO cell and may be modified post-
`
`
`
`
`
`
`
`translationally. In a specific embodiment, the fusion protein
`
`
`
`
`
`
`
`comprises amino acids 27-457 of SEQ ID NO:4 andis
`
`
`
`
`
`
`
`
`
`glycosylated at Asn residues 62, 94, 149, 222 and 308.
`
`
`
`
`
`
`
`
`[0031] The VEGF antagonist of the methods and formu-
`
`
`
`
`
`
`
`
`
`lations of the invention can be prepared by any suitable
`
`
`
`
`
`
`
`
`
`
`method knownin the art, or that comes to be known. The
`
`
`
`
`
`
`VEGFantagonist is preferably substantially free of protein
`
`
`
`
`
`
`
`
`contaminants at the time it is used to prepare the pharma-
`
`
`
`
`
`ceutically acceptable formulation. By “substantially free of
`
`
`
`
`
`
`
`protein contaminants” is meant, preferably, that at least 90%
`
`
`
`
`
`
`
`of the weight of protein of the VEGF-specific fusion protein
`
`
`
`
`
`
`antagonist preparation used for making a formulation is
`
`
`
`
`
`
`
`VEGFfusion protein antagonist protein, more preferably at
`
`
`
`
`
`
`
`
`
`least 95%, most preferably at least 99%. The fusion protein
`
`
`
`
`
`
`is preferably substantiallyfree of aggregates. “Substantially
`
`
`
`
`
`
`
`free of aggregates” means that at least 90% of the weight of
`
`
`
`
`
`
`
`
`fusion protein is not present in an aggregate at the time the
`
`
`
`
`
`
`
`fusion protein is used to prepare the pharmaceutically effec-
`
`
`
`
`
`
`
`
`
`tive formulation. The fusion protein of the methods and
`
`
`
`
`
`
`
`
`formulations of the invention may contain low or trace
`
`
`
`
`
`
`
`amounts of compounds as a results of the purification
`
`
`
`
`
`
`
`
`process, for example, lowor trace amounts ofcitrate and/or
`
`
`
`
`
`
`polysorbate. In one embodimentof the pre-lyophilized for-
`
`
`
`
`
`
`mulation of the invention containing about 50 mgof fusion
`
`
`
`
`
`
`protein/ml, citrate may be present at a concentration of about
`
`
`
`
`
`
`
`0.02 mM and/or polysorbate may be present at a concen-
`
`
`
`
`
`
`tration of about 0.0005%. If the pre-lyophilized formulation
`
`
`
`
`
`
`is reconstituted after lyophilization to half of the original
`
`
`
`
`
`
`
`volume(e.g., 100 mg/ml of fusion protein), the resulting
`
`
`
`
`
`
`concentrations may be 0.04 mM citrate and/or 0.001%
`
`polysorbate.
`
`
`
`
`
`
`
`
`
`Lyophilization and Lyophilized Formulations
`
`
`
`
`
`
`
`
`
`
`[0032]
`In one aspect ofthe invention, a pharmaceutically
`
`
`
`
`
`acceptable formulation comprising a VEGI -specific fusion
`
`
`
`
`
`
`protein antagonist is provided, wherein the formulation is a
`
`
`
`
`
`freeze-dried or lyophilized formulation. Lyophilized formu-
`
`
`
`
`
`
`
`lations can be reconstituted into solutions, suspensions,
`
`
`
`
`
`
`
`emulsions, or any other suitable form for administration or
`
`
`
`
`
`
`
`use. I yophilized formulations are typically first prepared as
`
`
`
`
`
`
`
`
`
`liquids, then frozen and lyophilized. The total liquid volume
`
`
`
`
`
`
`
`
`
`
`before lyophilization can be less, equal to, or more than, the
`
`
`
`
`
`
`final reconstituted volume of the lyophilized formulation.
`
`
`
`
`
`
`
`The lyophilization process is well knowntoa those of ordi-
`
`
`
`
`
`
`
`
`
`nary skill in the art, and typically includes sublimation of
`water from a frozen formulation under controlled condi-
`
`
`
`
`
`
`
`tions.
`
`
`
`
`
`
`
`
`[0033] Lyophilized formulations can be stored at a wide
`
`
`
`
`
`
`range of temperatures. Lyophilized formulations may be
`
`
`
`
`
`
`
`
`stored below 25° C., for example, refrigerated at 4° C., or at
`
`
`
`
`
`
`
`room temperature (e.g., approximately 25° C.). Preferably,
`
`
`
`
`
`
`
`
`lyophilized formulations are stored below about 25° C.,
`
`
`
`
`
`
`
`
`
`morepreferably, at about 4-20° C.; below about 4° C.; below
`
`
`
`
`
`
`
`
`
`
`
`about -20° C.; about —40° C.; about -70° C., or about -80°
`Cc.
`
`
`
`
`
`
`
`
`[0034] Lyophilized formulations are typically reconsti-
`
`
`
`
`
`
`
`tuted for use by addition of an aqueoussolution to dissolve
`
`
`
`
`
`
`
`the lyophilized formulation. A wide variety of aqueous
`
`
`
`
`
`
`solutions can be used to reconstitute a lyophilized formula-
`
`
`
`
`
`
`tion. Preferably, lyophilized formulations are reconstituted
`
`
`
`
`
`
`
`using water. Lyophilized formulations are preferably recon-
`
`
`
`
`
`
`
`stituted with a solution consisting essentially of water (e.g.,
`
`
`
`
`
`
`
`
`USP WEI, or water for injection) or bacteriostatic water
`
`
`
`
`
`
`
`
`
`(e.g., USP WFI with 0.9% benzyl] alcohol). However, solu-
`
`
`
`
`
`
`
`tions comprising buffers and/or excipients and/or one or
`
`
`
`
`
`
`
`more pharmacetically acceptable carries can also be used.
`
`
`
`
`
`
`
`[0035] Freeze-dried or lyophilized formulations are typi-
`
`
`
`
`
`
`
`
`
`cally prepared from liquids, that is, from solutions, suspen-
`
`
`
`
`
`
`
`
`
`
`sions, emulsions, and the like. Thus, the liquid that is ta
`
`
`
`
`
`
`undergo freeze-drying or lyophilization preferably com-
`
`
`
`
`
`
`
`prises all components desired in a final reconstituted liquid
`
`
`
`
`
`
`formulation. As a resull, when reconstituted, the freeze-dried
`
`
`
`
`
`
`
`or lyophilized formulation will render a desired liquid
`
`
`
`
`
`
`formulation upon reconstitution. A preferred liquid formu-
`
`
`
`
`
`
`lation used to generate a freeze-dried or lyophilized formu-
`
`
`
`
`
`
`lation comprises a VEGF-specific fusion protein antagonist
`
`
`
`
`
`
`in a pharmaceuticallyeffective amount, a buffer, a stabilizer,
`
`
`
`
`
`
`and a bulking agent. Freeze-dried or lyophilized formula-
`
`
`
`
`
`
`
`
`tions preferably comprise histidine, since histidine, in com-
`
`
`
`
`
`
`
`parison to phosphate,
`is more effective at stabilizing the
`
`
`
`
`
`
`
`
`fusion protein when the fusion protein is lyophilized.
`
`
`
`
`
`
`
`
`Organic cosolvents, such as PEG 3350, are used to stabilize
`
`
`
`
`
`
`
`
`the fusion protein when agitated, mixed, or handled. A
`
`
`
`
`
`
`
`lyoprotectant
`is preferably used in freeze-dried or lyo-
`
`
`
`
`
`
`philized formulations. Lyoprotectants help to maintain the
`
`
`
`
`
`
`
`
`secondary structure of proteins when freeze-dried or lyo-
`
`
`
`
`
`
`
`philized. Two preferred example lyoprotectants are glycine
`
`
`
`
`
`
`
`and sucrose, which are preferably used together.
`
`
`
`
`
`US 2006/0217311 Al
`
`
`
`Sep. 28, 2006
`
`
`
`
`
`
`
`
`
`Stable Liquid Formulations
`
`
`
`
`
`
`
`
`[0036]
`the invention provides a stable
`In one aspect,
`
`
`
`
`pharmaceutically acceptable formulation comprising a
`
`
`
`
`
`
`
`VEGE-specific fusion protein antagonist, wherein the for-
`
`
`
`
`
`
`mulation is a liquid formulation. Preferably,
`the liquid
`
`
`
`
`
`formulation comprises a pharmaceutically effective amount
`
`
`
`
`
`
`
`
`
`of the fusion protein. The formulation can also comprise one
`
`
`
`
`
`
`
`or more pharmaceutically acceptable carriers, buffers, bulk-
`
`
`
`
`
`
`ing agents, stabilizers, preservatives, and/or excipients. An
`
`
`
`
`
`example of a pharmaceutically acceptable liquid formula-
`
`
`
`
`
`
`tion comprises a VEGF -specific fusion protein antagonist in
`
`
`
`
`
`
`a pharmaceutically effective amount, a buffer, a co-solvent,
`and one or morestabilizers.
`
`
`
`
`
`
`
`
`
`
`[0037] A preferred liquid formulation comprises phos-
`
`
`
`
`
`
`
`
`phate buffer, an organic co-solvent, and one or more thermal
`
`
`
`
`
`
`
`
`stabilizers to minimize formation of aggregates and low
`
`
`
`
`
`
`
`
`molecular weight products when stored, and about 10 mg/ml
`
`
`
`
`
`
`
`
`to about 50 mg/ml fusion protein, wherein the formulation
`
`
`
`
`
`
`
`
`is from about pH 6.0-6.5. A preferred liquid formulation
`
`
`
`
`
`
`
`comprises about 5 mM phosphate buffer, about 5 mM
`
`
`
`
`
`
`
`
`
`citrate, about 100 mM NaCl, about 25% sucrose, and about
`
`
`
`
`
`
`
`
`10-50 mg/ml fusion protein, wherein the formulation is at a
`
`
`
`
`
`
`
`
`pH ofabout6.0; optionally polysorbate maybepresent(c.g.,
`
`
`
`
`
`
`
`
`0.1%polysorbate 20), Although cither NaCl or sucrose can
`
`
`
`
`
`
`
`be used as a stabilizer, a combination of NaCl and sucrose
`
`
`
`
`
`
`
`
`has been established to stabilize the fusion protein more
`
`
`
`
`
`
`effectively than either individual stabilizer alone.
`
`
`
`
`
`
`[0038]
`Stability is determined in a number of ways at
`
`
`
`
`
`
`
`specified time points, including determination of pH, visual
`
`
`
`
`
`
`inspection of color and appearance, determination of total
`
`
`
`
`
`
`
`
`
`protein content by methods known in the art, e.g.. UV
`
`
`
`
`
`spectroscopy, SDS-PAGE,size-exclusion HPLC, bioassay
`
`
`
`
`
`
`determination ofactivity, isoelectric focusing, and isoaspar-
`
`
`
`
`
`
`
`tate quantification. In one example of a bioassay useful for
`
`
`
`
`
`
`determining VEGF antagonist activity, a BAF/3 VEGFR1/
`
`
`
`
`
`
`EPORcell line is used to determine VEGF 165 binding by
`
`
`
`
`
`
`
`
`
`the VEGF-specific fusion protein antagonist of the inven-
`tion.
`
`
`
`
`
`
`
`
`
`
`
`[0039] Formulations, whether liquid or freeze-dried and
`
`
`
`
`
`
`lyophilized, can be stored in an oxygen-deprived environ-
`
`
`
`
`
`ment. Oxygen-deprived environments can be generated by
`
`
`
`
`
`
`
`
`
`
`storing the formulations under an mert gas such as, for
`
`
`
`
`
`example, argon, nitrogen, or helium.
`EXAMPLES
`
`
`
`
`
`
`
`
`[0040] Before the present methodsare described,it is to be
`
`
`
`
`
`
`
`understood that this invention is not limited to particular
`
`
`
`
`
`
`
`methods, and experimental conditions described, as such
`
`
`
`
`
`
`
`methods and conditions may vary.It is also to be understood
`
`
`
`
`
`
`
`
`
`the terminology used herein is for the purpose of
`that
`
`
`
`
`
`
`
`describing particular embodiments only, and is not intended
`
`
`
`
`
`
`
`
`
`
`to be limiting, since the scope of the present invention will
`
`
`
`
`
`
`be limited only to the appended claims.
`
`
`
`
`
`
`
`
`[0041] As used in this specification and the appended
`
`
`
`
`
`
`
`
`
`
`claims, the singular forms “a”, “an”, and “the” include plural
`
`
`
`
`
`
`
`references unless the context clearly dictates otherwise.
`
`
`
`
`
`
`
`Thus for example, a reference to “a method”includes one or
`
`
`
`
`
`
`
`
`
`more methods, and/or steps of the type described. herein
`
`
`
`
`
`
`
`
`and/or which will become apparent to thase persons skilled
`
`
`
`
`
`
`
`
`
`in the art upon reading, this disclosure and so forth.
`
`
`
`
`
`
`
`
`[0042] Unless defined otherwise, all technical and scien-
`
`
`
`
`
`
`
`
`
`tific terms used herein have the same meaning as commonly
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`understood by one ofordinary skill in the art to which this
`
`
`
`
`
`
`invention belongs. Although any methods and materials
`
`
`
`
`
`
`similar or equivalent to those described herein can be used
`
`
`
`
`
`
`
`
`
`in the practice or testing of the present
`invention,
`the
`
`
`
`
`
`
`
`preferred methods and materials are now described. All
`
`
`
`
`
`
`publications mentioned herein are incorporated herein by
`
`
`
`reference in their entirety.
` Example 1
`
`
`
`
`
`
`Stability of a 50 mg/ml Liquid Formulation of
`
`
`VEGF Trap
`
`
`
`
`
`[0043] A liquid formulation containing, 10 mM phosphate,
`
`
`
`
`
`
`
`
`50 mM NaCl, 0.1% polysorbate 20, 20% sucrose, and 50
`
`
`
`
`
`
`
`mg/ml VEGF trap (SEQ ID NO:4), pH 6.25, wasstored at
`
`
`
`
`
`
`
`
`
`
`
`5° C. and samples tested at 3, 6, 9, 12, 18 and 24 months.
`
`
`
`
`
`
`
`Stability was determined by SE-HPLC.Theresulls, shown
`
`
`
`
`
`
`
`
`
`in Table 1, showthat 98.6% and 98.3%ofVEGFtrap protein
`
`
`
`
`
`
`
`remain undegraded at 12 and 24 months, respectively.
`
`
`
`
`
`
`
`
`Turbidity was measured at OD,,, nm; and percent recovered
`
`
`
`
`protein bysize exclusion HPLC.
`
`TABLE1
`
`
`Stability of 50 mg/ml VEGF Trap Protein When
`
`
`
`
`
`
`Stored at_5° C.
`(VGFT-SS065
`
`
`
`
`
`
`
`Visual
`
`Months Appearance
`
`0
`Pass
`3
`Pass
`6
`Pass
`9
`Pass
`12
`Pass
`18
`Pass
`24
`Pass
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Turbidity
`0.00
`
`0.00
`
`0.01
`
`0.01
`
`0.01
`
`0.00
`
`0.00
`
`
`pH
`6.2
`6.2
`6.2
`63
`6.3
`6.3
`6.2
`
`
`
`
`
`
`
`
`
`
`
`
`
`% VEGF Trap
`
`
`Recovered
`